ATE404198T1 - Verbindungen mit einzigartiger cb1-rezeptor- bindungsselektivität und herstellungs- und anwendungsverfahren dafür - Google Patents

Verbindungen mit einzigartiger cb1-rezeptor- bindungsselektivität und herstellungs- und anwendungsverfahren dafür

Info

Publication number
ATE404198T1
ATE404198T1 AT03719602T AT03719602T ATE404198T1 AT E404198 T1 ATE404198 T1 AT E404198T1 AT 03719602 T AT03719602 T AT 03719602T AT 03719602 T AT03719602 T AT 03719602T AT E404198 T1 ATE404198 T1 AT E404198T1
Authority
AT
Austria
Prior art keywords
compounds
unique
production
methods
receptor binding
Prior art date
Application number
AT03719602T
Other languages
English (en)
Inventor
Brian Thomas
Herbert Seltzman
Maria Francisco
Original Assignee
Res Triangle Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Triangle Inst filed Critical Res Triangle Inst
Application granted granted Critical
Publication of ATE404198T1 publication Critical patent/ATE404198T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Lining Or Joining Of Plastics Or The Like (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03719602T 2002-04-15 2003-04-14 Verbindungen mit einzigartiger cb1-rezeptor- bindungsselektivität und herstellungs- und anwendungsverfahren dafür ATE404198T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/121,708 US6825209B2 (en) 2002-04-15 2002-04-15 Compounds having unique CB1 receptor binding selectivity and methods for their production and use

Publications (1)

Publication Number Publication Date
ATE404198T1 true ATE404198T1 (de) 2008-08-15

Family

ID=29214440

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03719602T ATE404198T1 (de) 2002-04-15 2003-04-14 Verbindungen mit einzigartiger cb1-rezeptor- bindungsselektivität und herstellungs- und anwendungsverfahren dafür

Country Status (7)

Country Link
US (1) US6825209B2 (de)
EP (1) EP1494673B1 (de)
AT (1) ATE404198T1 (de)
AU (1) AU2003223471B2 (de)
CA (1) CA2482004C (de)
DE (1) DE60322865D1 (de)
WO (1) WO2003088968A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7177738B2 (en) * 2001-05-30 2007-02-13 Alpine Electronics, Inc. Vehicle management system
AU2003267728A1 (en) * 2002-10-18 2004-05-04 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) * 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) * 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) * 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) * 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
JP4041153B2 (ja) * 2003-05-07 2008-01-30 ファイザー・プロダクツ・インク カンナビノイド受容体リガンドとその使用
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US20040259887A1 (en) * 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof
ATE440085T1 (de) * 2004-02-20 2009-09-15 Astrazeneca Ab 3-substituierte 1,5-diphenylpyrazolderivate, die sich als cb1-modulatoren eignen
FR2874012B1 (fr) * 2004-08-09 2008-08-22 Sanofi Synthelabo Derives de pyrrole, leur preparation et leur utlisation en therapeutique
EP1831177A1 (de) * 2004-12-23 2007-09-12 AstraZeneca AB Therapeutische mittel
FR2882365B1 (fr) * 2005-02-21 2007-09-07 Sanofi Aventis Sa Derives de 2-(1,5-diphenyl-1h-pyrazol-3-yl)-1,3,4-oxadiazole leur preparation et leur application en therapeutique
US7923465B2 (en) 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
EP1910290A2 (de) 2005-06-30 2008-04-16 Prosidion Limited Gpcr-agonisten
WO2007009690A1 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A Heterocyclyl-substituted pyrazoline compounds, their preparation and use as medicaments
GB0514738D0 (en) * 2005-07-19 2005-08-24 Astrazeneca Ab Therapeutic agents
CA2518579A1 (en) * 2005-08-05 2007-02-05 University Technologies International Inc. Method for appetite suppression
US20080193534A1 (en) * 2005-08-12 2008-08-14 Astrazeneca Ab Process
US20070060638A1 (en) * 2005-08-26 2007-03-15 Olmstead Mary C Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist
ES2289888B1 (es) * 2005-09-08 2008-12-16 Consejo Superior Investig. Cientificas Derivados de pirazolcarboxamida, su procedimiento de obtencion y sus aplicaciones como antagonistas/agonistas inversos del receptor cannabinoide cb1 y opioide mu.
EP1772449A1 (de) * 2005-10-05 2007-04-11 Bayer CropScience S.A. N-alkyl-heterocyclische carboxamide Derivate
CN100999517B (zh) 2006-01-11 2010-12-15 北京摩力克科技有限公司 吡唑甲酰胺衍生物,药物组合物和其制备方法
CN101062919B (zh) * 2006-04-26 2012-08-15 中国人民解放军军事医学科学院毒物药物研究所 4-甲基-1h-二芳基吡唑衍生物及其作为药物的用途
US7807765B2 (en) * 2006-05-31 2010-10-05 Rohm And Haas Company Heterocyclic latex copolymer and methods of making and using same
US20070287734A1 (en) * 2006-06-09 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
WO2007148062A1 (en) * 2006-06-20 2007-12-27 Astrazeneca Ab Therapeutic agents
US7875647B2 (en) * 2006-09-29 2011-01-25 Green Cross Corporation Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists
EP2121659B1 (de) 2006-12-18 2013-05-15 7TM Pharma A/S Modulatoren von cb1-rezeptoren
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
PE20081849A1 (es) 2007-01-04 2009-01-26 Prosidion Ltd Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
CL2008000018A1 (es) 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
US20100048632A1 (en) 2007-01-04 2010-02-25 Matthew Colin Thor Fyfe Piperidine GPCR Agonists
EA016507B1 (ru) 2007-01-04 2012-05-30 Прозидион Лимитед Пиперидиновые агонисты gpcr
TW200848039A (en) * 2007-02-09 2008-12-16 Astrazeneca Ab Pharmaceutical compositions
GB0702862D0 (en) * 2007-02-14 2007-03-28 Univ Aberdeen Therapeutic compounds
FR2919184A1 (fr) * 2007-07-26 2009-01-30 Sanofi Aventis Sa L'acide 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4- methylpyrazole-3-carboxylique, ses esters, ses sels pharmaceutiquement acceptables et leurs solvates pour leur utilisation comme medicament.
ES2291147B1 (es) * 2007-10-15 2008-11-01 Fundacion Instituto Mediterraneo Para La Biotecnologia Y La Investigacion Sanitaria (Imabis) Derivados pirazolicos de amidas de acidos grasos como activadores especificos de receptores ppar-alfa, procedimiento de preparacion y utilizacion.
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
CN102206182B (zh) * 2011-04-11 2013-03-13 中国药科大学 盐酸利莫那班的合成方法
CN103554025B (zh) * 2011-05-12 2016-08-10 范如霖 3-砒唑羧酸酰胺类化合物、其制备方法及其在制备作为cb1受体抑制剂药物中的应用
CN102250006B (zh) * 2011-05-12 2014-03-05 范如霖 3-吡唑羧酸酰胺类化合物、其制备方法及其在制备作为cb1受体抑制剂药物中的应用
US9133128B2 (en) * 2011-06-17 2015-09-15 Research Triangle Institute Pyrazole derivatives as cannabinoid receptor 1 antagonists
AU2017260706B2 (en) 2016-05-04 2023-05-11 Inmed Pharmaceuticals Inc. Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders
EP3684353A4 (de) 2017-09-22 2021-06-23 Inmed Pharmaceuticals Inc. Topische formulierungen von cannabinoiden und ihre verwendung zur schmerzbehandlung
IL284752B2 (en) 2019-01-15 2025-05-01 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Peripheral CB1 receptor inhibitors
IL305768A (en) 2021-03-12 2023-11-01 Bionanosim Bns Ltd Peripherally restricted cb1 receptor blockers and uses thereof
WO2025029961A1 (en) * 2023-07-31 2025-02-06 Makscientific, Llc Pharmaceutical compositions, and preparation and methods of use thereof
WO2025090133A1 (en) 2023-10-23 2025-05-01 Inmed Pharmaceuticals Inc. Compositions and methods for use of cannabinol compounds in neuroprotection
WO2025090587A1 (en) 2023-10-23 2025-05-01 Inmed Pharmaceuticals Inc. Cannabinoids compounds and their use in the treatment of neuronal disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993007294A1 (en) 1991-10-01 1993-04-15 The United States Of America, Represented By The Secretary, Department Of Health And Human Service A method of identifying ligands and antagonists of ligands
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2714057B1 (fr) 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
US5596106A (en) 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
FR2741621B1 (fr) 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
FR2742148B1 (fr) 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2758723B1 (fr) 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
KR20010021696A (ko) 1997-07-11 2001-03-15 미즈노 마사루 퀴놀린 화합물 및 그의 의약용도
AU1394899A (en) 1997-11-10 1999-05-31 Research Foundation Of The State University Of New York, The Opiate, cannabinoid, and estrogen receptors
AU766988B2 (en) 1998-04-21 2003-10-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cannabinoids as antioxidants and neuroprotectants
CA2330681C (en) 1998-05-29 2008-08-26 Andrea Giuffrida Control of pain with endogenous cannabinoids
HN1998000027A (es) 1998-08-19 1999-06-02 Bayer Ip Gmbh Arilsulfonamidas y analagos
FR2783246B1 (fr) 1998-09-11 2000-11-17 Aventis Pharma Sa Derives d'azetidine, leur preparation et les medicaments les contenant
FR2789079B3 (fr) 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
US6344481B1 (en) 1999-03-01 2002-02-05 Pfizer Inc. Thyromimetic antiobesity agents
WO2001004083A1 (en) 1999-07-07 2001-01-18 Innovet Italia S.R.L. Covalent derivatives of alkanolamides of monocarboxylic and dicarboxylic acids functionally active on the cb2 cannabinoid receptor
US6818640B1 (en) 1999-09-14 2004-11-16 Shionogi & Co., Ltd. 2-imino-1,3-thiazine derivatives
FR2800375B1 (fr) 1999-11-03 2004-07-23 Sanofi Synthelabo Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
FR2800372B1 (fr) 1999-11-03 2001-12-07 Sanofi Synthelabo Derives tricycliques d'acide 1-benzylpyrazole-3- carboxylique, leur preparation, les medicaments en contenant
CA2324800A1 (en) 1999-11-10 2001-05-10 Mary Anne Hickman Use of apo b secretion/mtp inhibitors
CA2324801A1 (en) 1999-11-10 2001-05-10 Andrew Gordon Swick Use of apo b secretion/mtp inhibitors and anti-obesity agents
CO5271688A1 (es) 1999-11-10 2003-04-30 Pfizer Prod Inc Uso de inhibidor de secrecion de apoliproteinas b y/o de proteina de transferencia de trigliceridos microsmales
FR2804604B1 (fr) 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
UA74367C2 (uk) 2000-03-23 2005-12-15 Сольве Фармас'Ютікалз Б.В. ПОХІДНІ 4,5-ДИГІДРО-1Н-ПІРАЗОЛУ, ЩО ВИЯВЛЯЮТЬ АНТАГОНІСТИЧНУ АКТИВНІСТЬ ЩОДО СВ<sub>1</sub>, СПОСІБ ЇХ ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ЇЇ ВИГОТОВЛЕННЯ, СПОСІБ ЛІКУВАННЯ ЗАХВОРЮВАНЬ (ВАРІАНТИ)
US6509367B1 (en) * 2001-09-22 2003-01-21 Virginia Commonwealth University Pyrazole cannabinoid agonist and antagonists

Also Published As

Publication number Publication date
US20030199536A1 (en) 2003-10-23
CA2482004C (en) 2011-06-07
EP1494673A1 (de) 2005-01-12
CA2482004A1 (en) 2003-10-30
EP1494673B1 (de) 2008-08-13
EP1494673A4 (de) 2006-01-18
AU2003223471A1 (en) 2003-11-03
AU2003223471B2 (en) 2006-11-16
WO2003088968A1 (en) 2003-10-30
DE60322865D1 (de) 2008-09-25
US6825209B2 (en) 2004-11-30

Similar Documents

Publication Publication Date Title
ATE404198T1 (de) Verbindungen mit einzigartiger cb1-rezeptor- bindungsselektivität und herstellungs- und anwendungsverfahren dafür
CY2013022I1 (el) Συνθεσεις για την θεραπευτικη αγωγη γαστρεντερικων διαταραχων
WO2004078116A3 (en) P38 inhibitors and methods of use thereof
TW200510416A (en) P38 inhibitors and methods of use thereof
WO2007051062A3 (en) Substituted dihydropyridines and methods of use
IL178334A0 (en) Selected cgrp antagonists, methods for the production thereof and their use as medicaments
TW200531689A (en) Therapeutic agents
CY1112505T1 (el) Ανοσοκατασταλτικες ενωσεις και συνθεσεις
NO2014009I2 (no) Forbindelser, farmasøytiske sammensetninger og anvendelser derav, samt fremgangsmåte for å fremstille nevnte forbindelser
IL158590A0 (en) Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes
IS2722B (is) 1, 2, 3, 4- Tetrasetin indól til meðhöndlunar á öndunarfærasjúkdómum
NO20053211D0 (no) Forbindelser for behandling av metabolske forstyrrelser.
ZA200502247B (en) Selected CGRP antagonists, method for production and use thereof as medicament.
GB0504828D0 (en) Therapeutic agents
TW200504034A (en) Therapeutic agents
TW200635903A (en) Therapeutic agents
TW200611702A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
DE60234616D1 (de) Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
GB0426313D0 (en) Therapeutic agents
MX2007002470A (es) Fenilaminotiazoles sustituidos y su uso.
LTC2805723I2 (lt) Kladribino režimas, skirtas išsėtinei sklerozei gydyti
DE502004011551D1 (de) 1,3,4-substituierte pyrazole als 5-ht rezeptor-antagonisten zur behandlung von psychosen und neurologischen störungen
TW200633986A (en) Therapeutic agents
ITMI20020773A1 (it) Farmaci per il trattamento dell&#39;artrite

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties